NPMA (China) grants conditional approval for molnupiravir to be used in adult patients who have mild to medium COVID infection and a high risk of progressing to severe cases
NPMA (China) grants conditional approval for the import of Merck's COVID-19 treatment, molnupiravir
Molnupiravir, is approved to be used in adult patients who have mild to medium COVID infection and a high risk of progressing to severe cases.
Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.